Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
Clinical trial NCT02698410 · COMPLETED
Trial details
- NCT number
- NCT02698410
- Sponsor
- Ipsen
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-01
- Primary completion
- 2019-02-08
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.